HUTCHMED Highlights Clinical Data to be Presented at Medical Conferences

Clinical Data to be Presented at ESMO and WCLC

HUTCHMED, a leading biopharmaceutical company focused on research and development of innovative cancer therapeutics, has announced clinical data to be presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer (WCLC).

ESMO Congress 2024

At the ESMO Congress 2024, held in Paris, France, from September 13–17, 2024, HUTCHMED will deliver clinical data on several of its investigational cancer therapies. These include:

• Oral presentation of data from the Phase III SAVANNAH study evaluating savolitinib, a next-generation RET inhibitor, in patients with advanced RET-mutant medullary thyroid cancer.
• Poster presentation of findings from the Phase II EV-1 study assessing elzosimatinib, a selective, orally administered, brain-penetrant, next-generation MST1/2 inhibitor, in patients with advanced NSCLC.
• Poster presentation of data from the Phase II GEMSTONE-302 study investigating fruquintinib, a highly selective and potent oral inhibitor of VEGFR1/2/3, in combination with camrelizumab, a humanized anti-PD-1 monoclonal antibody, in patients with locally advanced or metastatic urothelial carcinoma.

2024 World Conference of Lung Cancer

At the 2024 World Conference of Lung Cancer, held in Singapore from August 28–31, 2024, HUTCHMED will present the results of the following clinical studies:

• Oral presentation of data from the Phase III APOLLO study evaluating fruquintinib in combination with tremelimumab, a fully human monoclonal antibody targeting CTLA-4, in patients with previously untreated Stage IV non-small cell lung cancer (NSCLC).
• Poster presentation of long-term survival data from the Phase II GEMSTONE-201 study investigating fruquintinib in patients with advanced NSCLC.